Rash correlates with tumour response after cetuximab.
Susman
Ed
E
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology*; D000068818:Cetuximab; D002986:Clinical Trials as Topic; D005076:Exanthema / Q000139:chemically induced* / Q000473:pathology*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab